The Centre for Probe Development and Commercialization (CPDC) has launched Cadena Research, a new preclinical contract research organization (CRO) offering support for early-stage drug development in the radiopharmaceutical sector.
Cadena Research provides services including in vitro and in vivo research and development, screening, lead optimization, toxicology, dosimetry, imaging, and advanced radiochemistry capabilities. Based in Hamilton, Ontario, Canada, the organization also offers glucagon-like peptide (GLP) capabilities for investigational new drug (IND) studies.
Cadena Research is led by Martin Poirier, vice president of contract research, who has 25 years of operational experience. Poirier said the organization aims to accelerate the development of treatments and help grow the global radiopharmaceutical sector.
